George Ho, MD
Urology · Columbus, OHNPI 1255390852
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $54,535 of the $71,522 with a category attached, or 76.2%. 32 manufacturers reported payments, led by Astellas Pharma US Inc at 57.1% of the total. Reporting peaked in 2019 at $24,032 and has fallen 98.3% since, to $419 in 2025. Among urology clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 222 payments — averaging $322.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$41K
- Pfizer$22K
- Axonics, Inc.$3K
- Neotract Inc.$932
- Teleflex LLC$688
- Boston Scientific$568
- plus $3K from 26 others
What the payments were for
- Speaking & faculty fees$54,53576%
- Travel & lodging$8,68112%
- Food & beverage$7,26510%
- Education$1,0411%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 69 | $40,859 |
| Pfizer | 29 | $22,368 |
| Axonics, Inc. | 23 | $2,743 |
| Neotract Inc. | 9 | $932 |
| Teleflex LLC | 8 | $688 |
| Boston Scientific | 7 | $568 |
| Dentsply IH Inc. | 3 | $373 |
| AstraZeneca | 9 | $371 |
| Procept Biorobotics Corporation | 5 | $368 |
| Medtronic(2 entities) | 3 | $267 |
| Myovant Sciences Inc. | 8 | $257 |
| Foundation Medicine, Inc. | 2 | $246 |
| Rochester Medical Corporation | 6 | $176 |
| Progenics Pharmaceuticals, Inc. | 2 | $175 |
| Bluewind Medical | 1 | $149 |
| Calyxo, Inc. | 1 | $124 |
| Johnson & Johnson | 2 | $124 |
| Blue Earth Diagnostics | 5 | $121 |
| Bayer | 4 | $120 |
| Photocure Inc | 1 | $117 |
| Dentsply IH AB | 4 | $88 |
| AbbVie | 4 | $69 |
| Dendreon Pharmaceuticals LLC | 3 | $60 |
| Verity Pharmaceuticals Inc. | 2 | $33 |
| Antares Pharma, Inc. | 2 | $26 |
| Clarus Therapeutics Inc. | 2 | $21 |
| Merck | 1 | $17 |
| Tolmar Pharmaceuticals, Inc. | 1 | $15 |
| Urogen Pharma, Inc. | 1 | $13 |
| Coloplast | 1 | $11 |
| Avadel Specialty Pharmaceuticals, LLC | 1 | $11 |
| Travere Therapeutics, Inc. | 3 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XTANDI$43,243
- MYRBETRIQ$12,438
- ORGOVYX$4,950
- Axonics$2,427
- Bulkamid$1,638
- UroLift$1,186
- LoFric$357
- AQUABEAM SYSTEM$253
- FOUNDATIONONE LIQUID CDX$246
- INTERSTIM$153
- AMS 700$150
- REVI$149
- FOUNDATIONONE$126
- FOUNDATIONONE HEME$126
- FOUNDATIONONE CDX$126
- FOUNDATIONFOCUS$126
- CVAC Aspiration System$124
- UroLift System$122
- GreenLight XPS$121
- Cysview$117
How this compares
$71,522 in reported general payments places this provider in the 95th percentile of 485 urology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 60 | $843,230 |
| MyrbetriqMirabegron | 120 | $119,466 |
| GemtesaVibegron | 42 | $37,449 |
| Potassium Citrate ErPotassium Citrate | 115 | $16,600 |
| Dutasteride | 394 | $14,349 |
| Mirabegron ErMirabegron | 20 | $13,231 |
| Finasteride | 650 | $7,546 |
| Testosterone | 43 | $5,589 |
| Tamsulosin Hcl | 362 | $5,063 |
| Trospium Chloride | 42 | $3,636 |
| Solifenacin Succinate | 83 | $3,364 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 178 | $3,321 |
| Dutasteride-TamsulosinDutasteride/Tamsulosin Hcl | 12 | $2,663 |
| Testosterone Cypionate | 51 | $2,478 |
| Estradiol | 33 | $1,826 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $40,859 | $962,696180 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 485 urology providers in Ohio.
Other urology in Columbus
- Bodo KnudsenColumbus$108K
- Gregory LoweColumbus$106K
- Hiren PatelColumbus$54K
- Michael FarrellColumbus$52K
- Nicholas TadrosColumbus$32K
- Eric RiedingerColumbus$27K
- Eric SingerColumbus$25K
- Cheryl LeeColumbus$22K
- Matthew LeeColumbus$16K
- Lawrence GervasiMiddleburg Heights$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.